Effects of Statin Dose, Class, and Use Intensity on All-Cause Mortality in Patients with Type 2 Diabetes Mellitus
- PMID: 37111264
- PMCID: PMC10144141
- DOI: 10.3390/ph16040507
Effects of Statin Dose, Class, and Use Intensity on All-Cause Mortality in Patients with Type 2 Diabetes Mellitus
Abstract
Purpose: to examine the impact of statins on reducing all-cause mortality among individuals diagnosed with type 2 diabetes. This investigation explored the potential correlations between dosage, drug classification, and usage intensity with the observed outcomes.
Methods: The research sample consisted of individuals aged 40 years or older diagnosed with type 2 diabetes. Statin usage was determined as a frequent usage over a minimum of one month subsequent to type 2 diabetes diagnosis, where the average statin dose was ≥28 cumulative defined daily doses per year (cDDD-year). The analysis employed an inverse probability of treatment-weighted Cox hazard model, utilizing statin usage status as a time-varying variable, to evaluate the impact of statin use on all-cause mortality.
Results: The incidence of mortality was comparatively lower among the cohort of statin users (n = 50,804 (12.03%)), in contrast to nonusers (n = 118,765 (27.79%)). After adjustments, the hazard ratio (aHR; 95% confidence interval (CI)) for all-cause mortality was estimated to be 0.32 (0.31-0.33). Compared with nonusers, pitavastatin, rosuvastatin, pravastatin, simvastatin, atorvastatin, fluvastatin, and lovastatin users demonstrated significant reductions in all-cause mortality (aHRs (95% CIs) = 0.06 (0.04-0.09), 0.28 (0.27-0.29), 0.29 (0.28-0.31), 0.31 (0.30-0.32), 0.31 (0.30-0.32), 0.36 (0.35-0.38), and 0.48 (0.47-0.50), respectively). In Q1, Q2, Q3, and Q4 of cDDD-year, our multivariate analysis demonstrated significant reductions in all-cause mortality (aHRs (95% CIs) = 0.51 (0.5-0.52), 0.36 (0.35-0.37), 0.24 (0.23-0.25), and 0.13 (0.13-0.14), respectively; p for trend <0.0001). Because it had the lowest aHR (0.32), 0.86 DDD of statin was considered optimal.
Conclusions: In patients diagnosed with type 2 diabetes, consistent utilization of statins (≥28 cumulative defined daily doses per year) was shown to have a beneficial effect on all-cause mortality. Moreover, the risk of all-cause mortality decreased as the cumulative defined daily dose per year of statin increased.
Keywords: class of statin; dose-dependent; mortality; statin; type 2 diabetes.
Conflict of interest statement
The authors have no potential conflict of interest to declare. The data sets supporting the study conclusions are included in the manuscript.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10144141/bin/pharmaceuticals-16-00507-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10144141/bin/pharmaceuticals-16-00507-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10144141/bin/pharmaceuticals-16-00507-g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10144141/bin/pharmaceuticals-16-00507-g004.gif)
Similar articles
-
Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study.Eur J Clin Pharmacol. 2023 May;79(5):687-700. doi: 10.1007/s00228-023-03488-2. Epub 2023 Apr 3. Eur J Clin Pharmacol. 2023. PMID: 37010535
-
Optimal statin use for prevention of sepsis in type 2 diabetes mellitus.Diabetol Metab Syndr. 2023 Apr 19;15(1):75. doi: 10.1186/s13098-023-01041-w. Diabetol Metab Syndr. 2023. PMID: 37072863 Free PMC article.
-
Protective Effects Against Dementia Undergo Different Statin Type, Intensity, and Cumulative Dose in Older Adult Type 2 Diabetes Mellitus Patients.J Am Med Dir Assoc. 2024 Mar;25(3):470-479.e1. doi: 10.1016/j.jamda.2023.11.010. Epub 2023 Dec 18. J Am Med Dir Assoc. 2024. PMID: 38128583
-
Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus.Curr Atheroscler Rep. 2023 Sep;25(9):619-628. doi: 10.1007/s11883-023-01135-w. Epub 2023 Jul 29. Curr Atheroscler Rep. 2023. PMID: 37515725 Review.
-
Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Aug. Report No.: 14-05204-EF-2. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Aug. Report No.: 14-05204-EF-2. PMID: 27559556 Free Books & Documents. Review.
Cited by
-
Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association.Arch Med Sci. 2023 Nov 26;20(1):28-42. doi: 10.5114/aoms/175879. eCollection 2024. Arch Med Sci. 2023. PMID: 38414478 Free PMC article.
-
The Complementary Effects of Dabigatran Etexilate and Exercise Training on the Development and Stability of the Atherosclerotic Lesions in Diabetic ApoE Knockout Mice.Pharmaceuticals (Basel). 2023 Oct 2;16(10):1396. doi: 10.3390/ph16101396. Pharmaceuticals (Basel). 2023. PMID: 37895867 Free PMC article.
-
Association between Non-Lipid Residual Risk Factors and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Pitavastatin: An Observation from the REAL-CAD Study.J Atheroscler Thromb. 2024 Jan 1;31(1):61-80. doi: 10.5551/jat.64304. Epub 2023 Aug 11. J Atheroscler Thromb. 2024. PMID: 37574272 Free PMC article.
References
-
- GBD 2015 Risk Factors Collaborators Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1659–1724. doi: 10.1016/S0140-6736(16)31679-8. - DOI - PMC - PubMed
-
- Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., Fruchart J.C., James W.P., Loria C.M., Smith S.C., Jr., et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645. doi: 10.1161/CIRCULATIONAHA.109.192644. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials